SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES

Background. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a standard treatment for many patients with hematological malignancies. Complications of allo-HSCT are frequently associated either with a relapse of the underlying disease or a graft failure. Second transplantation can be offered to selected patients and is seen as the only curative option. In this paper, we report the experience of managing 24 such patients, all of whom underwent a second allo-HSCT.

Patients and methods. The research involved 24 patients (12 males/12 females) suffering from acute myeloid leukemia (AML, n = 14), acute lymphoblastic leukemia (ALL, n = 4), myeloproliferative disease (MPD, n = 3) and myelodysplastic syndrome (MDS, n = 3). The patients’ age ranged from 18 to 56 years, with the median age being 32 years. All the patients underwent a second allo-HSCT due to the disease relapse (n = 11) or graft failure (n = 13). 12 patients underwent a second allo-HSCT within the period of less than 6 months after the first allo-HSCT.

Results. Following the second allo-HSCT, engraftment occurred in 18/24 (75 %) patients, while 3 patients demonstrated graft failure and 3 — disease progression. Out of 18 patients having engrafted, 9 (50%) died during the first 100 days after allo-HSCT as a result of severe infections or visceral toxicity. 3 more lethal outcomes were recorded in later periods due to the disease progression. The overall mortality rate after the second allo-HSCT equalled 61.5 %. The median overall survival (OS) and disease-free survival (DFS) rates were 13.5 months and 10.59 months, respectively. Three-year OS and DFS were 38.5 % and 27.6 % respectively. Significant differences in terms of OS were detected for patients with a longer interval (>6 months) between the first and second allo-HSCT. The change of a donor was not associated with a better clinical outcome.

1. Savchenko V.G., Lyubimova L.S., Gribanova Е.O., Kuz’mina L.A. Bone marrow transplantation in patients with acute leukemia in complete remission and chronic myelolecosis in the chronic phase. Terapevticheskiy arhiv. 1999; 71(7): 27–32 (In Russian).

2. Rautenberg C., Germing U., Haas R., et al. Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment. Int. J. Mol. Sci. 2019; 20 (1): 228–48. DOI: 10.3390/ijms20010228

3. Giebel S., Labopin M., Potter M., et al. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphiapositive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2018; 96: 73–81. DOI: 10.1016/j.ejca.2018.03.018

4. Schmid C., Wreede L.C., Biezen A., et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. Haematologica. 2018; 103(2): 237–45. DOI: 10.3324/ haematol.2017.168716

5. Porter D.L., Alyea E.P., Antin J.H., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after allogeneic hematopoietic stem cell transplantation: report from the Committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16:1467–503. DOI: 10.1016/j.bbmt.2010.08.001

6. Levine J.E., Braun T., Penza S.L., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol..2002; 20: 405–12. DOI: 10.1200/JCO.20.2.405

7. Choi S.J., Lee J.H., Kim S., et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by GCSF-primed donor leukocyte infusion: A high incidence of isolated extramedullary relapse. Leukemia. 2004; 18: 1789–97.

8. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol..2007; 25: 4938–45. DOI: 10.1200/JCO.2007.11.6053

9. Lubbert M., Bertz H., Wasch R., et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant. 2010; 45: 627–32.

10. Loren A.W., Porter D.L. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2008; 41(5): 483–93. DOI: 10.1038/sj.bmt.1705898

11. Martino R., Badell I., Brunet S., et al. Second bone marrow transplantation for leukemia in untreated relapse. Bone Marrow Transplant. 1994; 14: 589–93.

12. Mrsíc M., Horowitz M.M., Atkinson K., et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 1992; 9: 269–75.

13. Radich J.P., Sanders J.E., Buckner C.D., et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with totalbody irradiation-containing regimens. J Clin Oncol. 1993; 11: 304–13.

14. Chiang K.Y., Weisdorf D.J., Davies S.M., et al. Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse. Bone Marrow Transplant. 1996; 17: 39–42.

15. Guièze R., Damaj G., Pereira B., et al. Management of myelodysplastic syndrome relapsing after allogeneic-hematopoietic stem cell transplantation: a study by the French society of bone marrow transplantation and cell therapies. Biol Blood Marrow Transplant. 2016; 22(2): 240–7. DOI: 10.1016/j.bbmt.2015.07.037

16. Schmid C., Labopin M., Nagler A., et al. Acute leukaemia working party of the European group for blood and marrow transplantation (EBMT). Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012; 119(6): 1599–606.

17. Schroeder T, Rachlis E, Bug G., et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions — a retrospective multicenter analysis from the German cooperative transplant study group. Biol Blood Marrow Transplant. 2015; 21(4): 186–93. DOI: 10.1038/bmt.2015.221

18. Wolff S.N. Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant. 2002; 29: 545–52. DOI: 10.1038/sj.bmt.1703389

19. Olsson R., Remberger M. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplantation. 2013; 48: 537–43. DOI: 10.1038/ bmt.2013.32

20. Davies S.M., Kollman C., Anasetti C., et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood. 2000; 96 (13): 4096–102.

21. Anasetti C., Amos D., Beatty P.G., et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989; 320: 197–204. DOI: 10.1056/ NEJM198901263200401

22. Rondón G., Saliba R., Khouri I., et al. Long Term Follow Up Of Patients Who Experienced Graft failure Post Allogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis Biol Blood Marrow Transplant. 2008; 14(8): 859– 66. DOI: 10.1016/j.bbmt.2008.05.005

23. Mattsson J., Ringdén O., Storb A. Graft Failure after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2008; 14(Suppl 1): 165–70. DOI: 10.1016/j.bbmt.2007.10.025

24. Remberger M., Ringden O., Ljungman P., et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1998; 22: 73–8. DOI: 10.1038/sj.bmt.1701290

25. Larocca A., Piaggio G., Podesta M., et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica. 2006; 91: 935–40.

26. Bittencourt H., Rocha V., Filion A., et al. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders. Bone Marrow Transplantation. 2005; 36: 431–5. DOI: 10.1038/sj.bmt.1705072

27. Nemunaitis J., Singer J.W., Buckner C.D., et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood. 1990; 76: 245–53.

28. Weisdorf D.J., Verfaillie C.M., Davies S.M., et al. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood. 1995; 85: 3452–6.

29. Remberger M., Mattsson J., Olsson R., et al. Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. Clin Transplant. 2011; 25: 68–76. DOI: 10.1111/j.1399-0012.2010.01324.x

30. Schriber J., Agovi M., Ho V., et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant. 2005; 16: 1099–106. DOI: 10.1016/j.bbmt.2010.02.013

31. Kanda J., Horwitz M.E., Long G.D., et al. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graf,t failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2012; 47: 700–5. DOI: 10.1038/bmt.2011.158

32. Sumi M., Shimizu I., Sato K., et al. Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation. Int J Hematol. 2010; 92: 744–50. DOI: 10.1007/s12185-010-0714-6

33. Ayas M., Eapen M., Le-Rademacher J., et al. Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. Biol Blood Marrow Transplant. 2015; 21(10): 1790–5. DOI: 10.1016/j. bbmt.2015.06.012

34. Horan J.T., Carreras J., Tarima S., et al. Risk factors affecting outcome of second HLA-matched sibling donor transplantations for graft failure in severe acquired aplastic anemia. Biol Blood Marrow Transplant. 2009; 15: 626–31.

35. Arfons L.M., Tomblyn M., Rocha V., et al. Second hematopoietic stem cell transplantation in myeloid malignancies. Curr Opin Hematol. 2009; 16: 112–23. DOI: 10.1097/MOH.0b013e3283257a87

36. Byrne B.J., Horwitz M., Long G.D., et al. Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection. Bone Marrow Transplant. 2008; 41: 39–43.

37. Fernandes J., Rocha V., Robin M., et al. Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. Br J Haematol. 2007; 137: 248–51. DOI: 10.1111/j.1365-2141.2007.06562.x

38. Lund T.C., Liegel J., Bejanyan N. et al. Second allogeneic hematopoietic cell transplantation for graft failure: Poor outcomes for neutropenic graft failure. Am. J. Hematol. 2015; 90: 892–6. DOI: 10.1016/j.bbmt.2014.11.242

39. Andreola G., Labopin M., Beelen D., et al. Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of greater than or equal to 10 years. Bone Marrow Transplant. 2015; 50(12): 1508–12. DOI: 10.1038/bmt.2015.193

40. Ruutu T., de Wreede L.C., van Biezen A., et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplantation. 2015; 9: 1–9.